Claims for Patent: 10,300,116

Summary for Patent: 10,300,116

Title:	Treatment for BK polyomavirus infection
Abstract:	The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen.
Inventor(s):	Moss; Ronald D. (Encinitas, CA)
Assignee:	Ansun Biopharma, Inc. (San Diego, CA)
Application Number:	14/894,918
Patent Claims:	1. A method of treating an infection by a BK polyomavirus or a BK polyomavirus-associated disorder in a subject, the method comprising administering to the subject an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO:14. 2. A method of reducing the risk or severity of an infection by BK polyomavirus or a BK polyomavirus-associated disorder in a subject, the method comprising administering to the subject an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO:14. 3. The method of claim 1, comprising administering a composition comprising microparticles comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO:14. 4. The method of claim 1, wherein the agent is not systemically administered. 5. The method of claim 1, wherein the subject is immunocompromised. 6. The method of claim 1, wherein the infection is associated with an event selected from the group consisting of: an HIV infection, cessation of immunosuppressive therapy, commencement of antiviral therapy, and monoclonal antibody autoimmune disease therapy. 7. The method of claim 1, wherein the subject is a transplant patient undergoing immunosuppressive therapy. 8. The method of claim 1, wherein the subject is being treated with an immunomodulatory agent that reduces one or more aspects of immune function. 9. The method of claim 8, wherein the immunomodulatory agent is selected from the group consisting of natalizumab, rituximab, efalizumab and infliximab. 10. The method of claim 1, wherein the polyomavirus binds a sialic acid-containing component on the surface of a target cell. 11. The method of claim 1, wherein the subject has undergone haematopoietic stem cell transplant or is being prepared for haematopoietic stem cell transplant. 12. The method of claim 1, wherein the disorder is BKV nephropathy. 13. The method of claim 1, wherein the disorder is nephritis. 14. The method of claim 1, wherein the disorder is hemorrhagic cystitis. 15. The method of claim 1, wherein the disorder is ureteral stenosis. 16. The method of claim 1, wherein the subject has undergone solid organ transplant or is being treated in preparation for solid organ transplant. 17. The method of claim 1, wherein the disorder is lupus. 18. The method of claim 1, wherein the agent is administered to the kidneys. 19. The method of claim 1, wherein the agent is administered to the ureter. 20. The method of claim 1, wherein the agent is administered to the bladder. 21. The method of claim 1, wherein the agent is administered topically. 22. The method of claim 1, wherein the agent is administered by infusion into the kidneys. 23. The method of claim 1, wherein the agent is administered by infusion into the bladder. 24. The method of claim 1, wherein the agent is administered by catheter into the bladder. 25. The method of claim 1, wherein the administration of the agent having sialidase activity causes one or more of: a reduction of dysuria, a reduction of frequency of urination, a reduction of subrapublic pain, a reduction of hematuria, a decrease in symptoms associated with nephropathy, and a reduction of BKPyV viral load.

Details for Patent 10,300,116

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-06-10
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2033-06-10
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10/27/2003		2033-06-10